- RBC's Michael Yee maintains an Outperform rating on Ariad Pharmaceuticals (NASDAQ:ARIA).
- Yee is looking forward to Iclusig data to be presented at a meeting of the American Society of Hematology this December.
- Price target is $28, representing a 25% upside from Friday's close.
- See also: Iclusig TRx +5.4% w/w